Basilea’s prognosis looks good. Multiple licensing/distribution agreements announced for launched assets Cresemba and Zevtera should drive top-line growth faster than we had expected. Major deals include; Cresemba in Europe (ex Nordics), Russia, Turkey and Israel with Pfizer (CHF70m upfront plus up to $427m in regulatory and sales milestones and mid-teen royalties), Zevtera in China with CR Gosun, and in Europe with Cardiome. These licensing and distribution deals validate the commercia
11 Oct 2017
- The future looks bright
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
- The future looks bright
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
11 Oct 2017 -
Author:
Dr Susie Jana -
Pages:
15
Basilea’s prognosis looks good. Multiple licensing/distribution agreements announced for launched assets Cresemba and Zevtera should drive top-line growth faster than we had expected. Major deals include; Cresemba in Europe (ex Nordics), Russia, Turkey and Israel with Pfizer (CHF70m upfront plus up to $427m in regulatory and sales milestones and mid-teen royalties), Zevtera in China with CR Gosun, and in Europe with Cardiome. These licensing and distribution deals validate the commercia